Clinical Trial Search

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Overall Response (OR) Rate — 0.07 Proportion of participants

Primary: Number of Participants With Objective Response — 1; 2; 14; 6 Participants

Primary: 1 Year Progression-free Survival Rate — 0.74 percentage of participants

Primary: Clinical Response Rate — 1; 7; 0; 8 Participants

Primary: Progression-free Survival — 89 percentage of participants

Primary: Progression-free Survival at 2 Years — 76; 80 percentage of participants — p=0.11

Primary: Maximum Tolerated Dose of CpG 7909 as Determined Using the Number of Participants With a DLT at Each Dose Level — 0; 1; 0; 1 participants

Primary: Assessment of Tumor Response — 30.3; 54.5 percentage of participants

Primary: Survival at 1 Year After Transplantation — 10; 6 participants

Primary: Complete Remission — 10 participants

Primary: Progression-free Survival (PFS) at 2 Years — 69 percentage of participants

Primary: Overall Response Rate — 53.3; 76.1 percentage of participants — p=0.29

Primary: Percentage of Participants With 3-year Progression-free Survival (PFS) — 90 percentage of participants

Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…

Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability

Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value

Primary: Number of Participants With Confirmed Response, Including Participants With Complete Response (CR), Clinical Complete Response (CCR), and Partial Response (PR) — 72…

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Overall Response Rate as Assessed According to the"Revised Response Criteria for Malignant Lymphoma" (Cheson 2007). — 5; 2; 7; 1 Participants

Primary: Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment — 0.69; 0.53 proportion

Primary: 3 Years Event-free Survival — 51; 56; 126; 123 Participants

Primary: Proportion of Confirmed Tumor Response (Complete Response [CR], Unconfirmed CR, and Partial Response) — 0.48 proportion of participants

Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519

Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants

Primary: Progression-free Survival (PFS) — 18 participants

Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 29; 49; 11; 15 participants

Primary: Proportion of Patients With CNS Involvement by B-cell NHL, Relapsed PCNSL, or Relapsed PIOL Who Are Alive and Progression-free at One Year — 28 Participants

Primary: Disease-free Survival at 1 Year — 0.818; 0.90 years